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In 2013,  the  WHO  Strategic  Advisory  Group  of  Experts  on  Immunization  (SAGE)  requested  WHO  to
develop  a process  and  a  plan  to  move  the  maternal  immunization  agenda  forward  in support  of an
increased  alignment  of  data  safety  evidence,  public  health  needs,  and  regulatory  processes.  A key
challenge  identiﬁed  was  the continued  need  for harmonization  of  maternal  adverse  event  following
immunization  (AEFI)  research  and  surveillance  efforts  within  developing  and  developed  country  con-
texts. We  conducted  a systematic  review  as  a preliminary  step  in  the  development  of standardized  AEFI
deﬁnitions  for use  in  maternal  and  neonatal  clinical  trials,  post-licensure  surveillance,  and  other  vac-
cine  studies.  We  documented  the  current  extent  and  nature  of  variability  in  AEFI  deﬁnitions  and  adverse
event  reporting  among  74  maternal  immunization  studies,  which  reported  a total  of 240  different  types
of  adverse  events.  Forty-nine  studies  provided  explicit  AEFI  case deﬁnitions  describing  35 separate  types
of AEFIs.  We  identiﬁed  variability  in  how  AEFIs  were  determined  to be present,  in how  AEFI deﬁnitions
were  applied,  and  in  the  ways  that  AEFIs  were  reported.  Deﬁnitions  for key  maternal/neonatal  AEFIs
differed  on  four  discrete  attributes:  overall  level  of detail,  physiological  and  temporal  boundaries  and
cut-offs, severity  strata,  and  standards  used.  Our  ﬁndings  suggest  that  investigators  may  proactively
address  these  inconsistencies  through  comprehensive  and  consistent  reporting  of  AEFI deﬁnitions  and
outcomes  in  future  publications.  In addition,  efforts  to develop  standardized  AEFI  deﬁnitions  should  gen-
erate deﬁnitions  of  sufﬁcient  detail  and  consistency  of  language  to avoid  the  ambiguities  we identiﬁed  in
reviewed  articles,  while  remaining  practically  applicable  given  the constraints  of low-resource  contexts
such as  limited  diagnostic  capacity  and high  patient  throughput.
©  2015  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
Since 1990, the world has experienced a dramatic decrease in
arly childhood mortality. In 2013, the global under-ﬁve mortality
ate (U5MR) was 46 deaths per 1000 live births, nearly half the rate
5MR of 90 deaths per 1000 live births in 1990 [1]. However, the
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rate of this reduction in under-ﬁve mortality is still insufﬁcient to
reach the Millennium Development Goals’ target of a two-thirds
reduction of 1990 mortality levels by the year 2015 [2,3].
Compared to under-ﬁve mortality, declines in newborn mortal-
ity have been much slower to materialize. As of 2012, nearly 40% of
all under-ﬁve child deaths occur in the neonatal period, i.e., babies
in their ﬁrst 28 days of life [4]. Additionally, in developing countries,
nearly half of all mothers and newborns fail to receive skilled care
during and immediately after birth. The World Health Organization
(WHO) estimates that up to two-thirds of newborn deaths can be
prevented if known, effective health measures are provided at birth
and during the ﬁrst week of life [4].
A potential strategy to address this global health need is
the immunization of pregnant women  to prevent diseases in
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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heir newborn children. Trans-placental transfer of antibodies has
een demonstrated in several studies, and may confer protec-
ion against inﬂuenza during a newborn’s ﬁrst months of life
5]. This strategy is buoyed by the success of the global Mater-
al Neonatal Tetanus Elimination Initiative and recent vaccine
tudies demonstrating that immunization of pregnant women
ecreases newborn inﬂuenza [6,7]. However, there are chal-
enges to introducing immunization programs in antenatal care
n resource-poor settings, requiring careful consideration of exist-
ng regulatory processes and expansion of the evidence base to
ake into account local public health needs to inform maternal
mmunization programs and policy [8,9]. The WHO/PATH Mater-
al Inﬂuenza Immunization Project aims to address some of these
hallenges – speciﬁcally with respect to vaccine distribution, logis-
ics, and potentially vaccine hesitancy and uptake – by promoting
he integration of immunization into antenatal care platforms in
ow- and middle-income countries [10].
There are limitations to vaccine safety data in pregnant women
s pregnant women are seldom included in clinical trials [11]. Most
afety information comes from observational studies and analysis
f post-licensure surveillance systems, such as those for inﬂuenza
accines [12]. In 2014, the WHO  Global Advisory Committee on Vac-
ine Safety (GACVS) reviewed inactivated inﬂuenza vaccine safety
n pregnancy and found no safety signals [13], and three recent
ystematic reviews of inﬂuenza vaccine safety in pregnancy have
lso been reassuring [14–16]. Nevertheless, the absence of global
tandard deﬁnitions for maternal immunization adverse events
inders comparisons of safety data across studies and geographic
egions. For these reasons, the WHO  and Brighton Collaboration
re developing standardized adverse event deﬁnitions and repor-
ing practices for use in clinical trials in pregnant women and other
ost-licensure vaccine safety monitoring.
The objective of this systematic review is to determine the
xtent and nature of variability in AEFI deﬁnitions and adverse
vent reporting among maternal immunization studies. The review
ims to characterize the heterogeneity of AEFI deﬁnitions and
eporting methods, which will directly inform ongoing vaccine
afety standardization efforts for the purposes of clinical trial
esign as well as vaccine pharmacovigilance after licensing. These
fforts will enhance collection, reporting, and comparison of clin-
cal and post-marketing surveillance safety data—advancing our
ollective understanding of vaccine safety in pregnancy, and con-
ributing to the harmonization of vaccine pharmacovigilance.
. Methods
.1. Eligibility criteria and assessment
.1.1. Types of studies
We  included randomized controlled trials and observational
tudies that deﬁne one or more AEFIs for the purpose of safety
onitoring. We  also included reviews of maternal immunization
tudies; reviews were thought to potentially contain abstracted
nformation on AEFI deﬁnitions that may  not have existed, either at
ll or at the same level of detail, in the source publications. Mater-
al immunization reviews were therefore included to ensure that
his content was not overlooked. We  did not include unpublished
tudies..1.2. Types of participants
Studies chosen for review included pregnant women  of all ages.
tudies that did not explicitly include pregnant women, either
xclusively or as part of an at-risk demographic, were excluded.3 (2015) 6453–6465
2.1.3. Types of interventions
Eligible interventions included all vaccines evaluated in
pregnant women.
2.1.4. Types of comparisons
We  included studies making any relevant comparisons of vac-
cines against a control, such as placebo, unexposed or untreated
group, or alternate vaccine formulation.
2.1.5. Types of outcome measures
Acceptable outcome measures included intervention efﬁcacy,
effectiveness, or safety. Speciﬁcally, studies that did not evaluate
vaccine safety as a primary outcome were included if maternal,
childbirth, or neonatal safety or adverse event data were reported.
2.1.6. Other selection criteria
Study setting had no impact on inclusion. We included stud-
ies conducted in any country or region, in rural, urban, or mixed
contexts, and in any participant setting such as in-hospital or in-
community. Five studies published in languages other than English
were considered for inclusion, but none were included in the ﬁnal
review due to lack of translation capacity. There was no constraint
on date of publication.
2.2. Search strategy
We  conducted a comprehensive and systematic search of pub-
lished literature potentially containing data on maternal and
neonatal adverse events following maternal immunization (Fig. 1).
Sources included all published maternal immunization studies
conducted to date (randomized controlled trials and observational
studies), identiﬁed via searches of PubMed, EMBASE, Web  of Sci-
ence, and the Cochrane Database. The search strategy used for this
review was  derived from prior work by Bonhoeffer et al including
a systematic review of vaccine safety data reporting [17]. Publi-
cations citing key papers that evaluated or attempted to establish
immunization study reporting standards (e.g. Bonhoeffer et al. [17])
were also included in the search process. Supplementary Table 1
details our maternal AEFI search strategy on PubMed and EMBASE;
Fig. 1 indicates the total number of results from all searches.
2.3. Screening and data extraction
The initial screening was  conducted by one reviewer; a two-
reviewer system was employed throughout the remainder of the
review workﬂow. We  imported search results into Endnote X5, and
one reviewer (T.R.F.) screened titles and abstracts for eligibility.
We discarded articles if their titles and abstracts clearly bore no
relevance to this review. We retrieved full texts of eligible stud-
ies, and discarded inaccessible studies (six articles published prior
to 2000, were inaccessible). Consensus and/or discussion with a
second reviewer (D. N.) resolved uncertainty during the screening
process with regard to inclusion/exclusion of studies. We  recorded
the rationale for study exclusion as part of the screening process.
The objective of our review was to determine the variance
in AEFI deﬁnitions across all maternal immunization literature
irrespective of study design, rigor, outcome, or potential bias.
Therefore, a methodological study quality assessment (e.g., a Grad-
ing of Recommendations Assessment, Development and Evaluation
(GRADE) analysis) was  not required for the purposes of this
review. Studies included in this review were neither assessed
for, nor ranked on the basis of, limitations in design or possible
bias.
We abstracted data from all research studies and publica-
tions meeting the inclusion criteria into an Excel workbook
(Supplemental Table 2). We  compiled additional data required
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5,488  title s and  abstra cts  identified  in PubMe d, Cochrane  Libra ry, EMBASE,   
Web of  Science,  and  WHO Re gional  Databa ses
121 papers reviewed in detail 
74 paper s ide ntified  for data abstra ction 
74 pa per s reporte d on matern al or ne onatal  adverse 
event s followin g immun ization  duri ng pre gnan cy 
47 papers excluded for  
following reasons: 
- No ana lysis of  vaccine safet y as 
primary or  second ary outcom e, 
and safety  da ta not availa ble from 
investigators  (23 ) 
- Article  is a dis cussion,  letter to 
editor or  subject review (1 3)  
- Pregnant women no t targ et 
population  (6) 
- Pap er not  in Engli sh and not 
transla tabl e (5) 
5,367
records/dupli cates/inac cessible 
articles ex cluded 
Fig. 1. Systematic rev
Table 1
Summary characteristics of included studies.
Number of papers
Selected publications by type
Study type
Retrospective cohort 30
Prospective cohort 24
Review 10
RCT 10
Cross-sectional 3
Case-control 2
Before/after 1
Selected publications by location
Continent
North America 35
Europe 15
South America 7
Asia 6
Africa 2
Australia 0
Multiple 9
Selected publications by vaccine
Vaccine
Inﬂuenza 37
Yellow fever 5
Tdap 4
Rubella 4
Varicella 2
Group B streptococcus 2
Hepatitis 2
HIV 2
Pneumococcal 2
HPV 1
Cholera 1
Cytomegalovirus 1
Herpes simplex 1
Meningococcal 1
Polio 1
Rabies 1
Respiratory syncytial virus 1
TT  1
Multiple 5iew workﬂow.
to fully characterize AEFI deﬁnitions used into a set of queries.
We contacted study investigators as necessary to request study
protocols and/or to address omitted or incomplete data on
adverse event deﬁnitions. We tracked communication with study
investigators over the course of the review to ensure complete
follow-up.
2.4. AEFI deﬁnitions and reported outcomes
We abstracted detailed information speciﬁc to AEFI case deﬁ-
nitions into a comprehensive AEFI deﬁnition table (Supplemental
Table 3). This table includes all additional unpublished informa-
tion regarding AEFI deﬁnitions obtained via communication with
study authors. Additionally, we  abstracted detailed information
speciﬁc to monitored and/or reported adverse event outcomes
into a reported outcomes table (Supplemental Table 4). This table
includes all reported or monitored maternal, fetal, and neonatal
outcomes, irrespective of whether any study provided a case deﬁ-
nition or classiﬁcation code for the outcome.
Prior to performing analyses, we removed duplicate case def-
initions and deﬁnitions with minor (i.e., typographical and/or
non-semantically signiﬁcant, such as “fetal death” versus “death,
foetal”) variations. However, we  separately listed AEFIs that share
similar deﬁnitions but are assigned different names. For example,
“stillbirth” and “late fetal death” are separately listed despite both
being deﬁned as “fetal death occurring at or after 20 weeks ges-
tation.” Similarly, we  separately listed deﬁnitions for a single AEFI
that share similar criteria (e.g., birth weight) but otherwise demon-
strate semantically signiﬁcant differences (for example, “birth after
20 weeks” versus “birth at or after 20 weeks”). Such AEFI names
and deﬁnitions are considered “unique” for the purposes of our
review.
2.5. AnalysisData analysis was  speciﬁcally tailored to provide the WHO
and Brighton Collaboration a comprehensive overview of the het-
erogeneity among AEFI deﬁnitions and reporting methods in the
maternal immunization literature.
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We  performed the following analyses:
(a) Ranking of reported outcomes by frequency, using a series of
generalized terms (e.g., miscarriage, preterm birth, stillbirth,
etc.) to categorize each type of deﬁnition;
b) Enumeration of studies providing AEFI deﬁnitions and/or infor-
mation regarding classiﬁcation systems used;
(c) Classiﬁcation of AEFIs by individual affected (mother, fetus, or
neonate);
d) Ranking of AEFIs by frequency of deﬁnition and/or monitoring;
e) Assessment of where in selected papers AEFIs are typically
deﬁned and/or reported on;
(f) Characterization of inconsistency in AEFI names and deﬁnitions,
in terms of overall detail and terminology, thresholds and cut-
offs, severity strata, and standards used; and
g) Assessment of differences in studies’ deﬁnitions of what con-
stitutes an adverse event.
. Results
.1. Study selection and characteristics
Out of a total of 5488 titles identiﬁed from electronic searches,
21 titles were selected as potentially relevant. All 121 papers
ere assessed for eligibility; following assessment, 47 papers were
xcluded with reason, and the remaining 74 papers were included
n the review (Fig. 1). Of the 74 selected publications, ten were
reviously published reviews.
Half of the selected studies (37) focused on inﬂuenza vaccine,
ollowed by yellow fever vaccines (5 studies), tetanus, diphthe-
ia and acellular pertussis (Tdap) vaccine (4), and rubella vaccines
4) (Table 1). Other vaccines investigated included tetanus toxoid
nd vaccines against pertussis, diphtheria, varicella, group B strep-
ococcus, hepatitis, human immunodeﬁciency virus (HIV), human
apillomavirus (HPV), pneumococcal, cholera, cytomegalovirus,
erpes simplex, meningococcal, polio, rabies, and respiratory syn-
ytial virus. Five papers (of which three were reviews) examined
accines against more than one pathogen.
The majority of studies were conducted in North America (35)
r Europe (15) (Table 1). Of note, only two studies and two reviews
ere exclusively conducted in (or, in the case of reviews, provided
EFI deﬁnitions for studies exclusively conducted in) lower- or
ower-middle-income countries [18–21]. Table 2 details these and
ther key characteristics of each study.
.2. Reported adverse event outcomes
A total of 240 adverse events were reported among all selected
ublications (Supplemental Table 4). A signiﬁcant proportion of
hese described typical pregnancy complications and a variety of
ongenital abnormalities. The speciﬁcity of adverse event repor-
ing varied widely, with some events (e.g., “abnormal pregnancy,”
local reaction”) being vaguely deﬁned or encompassing a range
f adverse events. However, all reported AEFI deﬁnitions fell natu-
ally within one of a series of AE categories speciﬁc to the AE target
mother, fetus, or neonate) (Table 4).
Of the 240 identiﬁed adverse events, 100 were speciﬁc to the
other, 21 to the fetus, and 119 to the neonate. Seventy-seven of
he 119 neonate-speciﬁc adverse events were categorized as con-
enital malformations or abnormalities. Table 3 lists the ten adverse
vents most frequently reported..3. Provision of AEFI deﬁnitions or classiﬁcations
Of the 74 selected studies, 49 provided one or more case deﬁ-
itions describing a total of 35 AEFIs. Across all studies, a total of3 (2015) 6453–6465
77 “unique” AEFI case deﬁnitions (excluding typographical or non-
semantically signiﬁcant variations) were found. Of the 77 unique
case deﬁnitions, 11 deﬁnitions came from studies conducted in
low- and lower-middle-income countries. The deﬁned adverse
events ranged in speciﬁcity, though most tended toward describ-
ing a single phenomenon (e.g., pre-eclampsia) rather than a group
of related phenomena (e.g., “local reaction”). The most frequently
deﬁned AEFIs (stillbirth, miscarriage, preterm birth) were also the
most often reported adverse events (Table 3). However, deﬁnitions
were notably few in number for commonly expected or minor AEFIs
such as site pain or fever. Table 4 lists all unique AEFI names and
deﬁnitions, grouped by individual affected.
A substantial number of included studies (25) did not provide
any AEFI deﬁnitions, but were included due to the reporting of AEFIs
during pregnancy and the newborn period. Many of these studies
cited the use of one of a number of adverse event classiﬁcation
systems in lieu of providing deﬁnitions (Supplemental Table 3);
speciﬁc codes for some AEs were provided (Supplemental Table 4).
Of note, most of these studies were retrospective analyses drawing
data from registries and/or patient records.
3.4. Consistency of AEFI reporting
Of those studies providing AEFI deﬁnitions, most (particularly
those examining maternal/fetal/neonatal AEFIs as the primary out-
come) deﬁned key AEFIs in Section 2 and subsequently reported
on each in Section 3 (Supplemental Table 3). In total, 52 studies
adhered to this reporting standard; of these studies, 38 reported
on AEFIs as a primary outcome.
Studies that monitored or assessed a wide variety of adverse
events, such as congenital abnormalities, typically speciﬁed a
classiﬁcation system used to detect or categorize adverse events
(Supplemental Table 4). Classiﬁcation systems in typical use
included the International Classiﬁcation of Diseases revision 9 (ICD-
9) and the Medical Dictionary for Regulatory Activities (MedDRA).
These studies often provided an exhaustive list of detected events
in Section 3 without speciﬁc deﬁnitions.
3.5. Variability in adverse event deﬁnitions
Adverse event deﬁnitions were found to vary substantially
between studies, as shown in Table 4. Speciﬁcally, deﬁnitions for
key maternal/neonatal AEFIs differed on four attributes: overall
level of detail, physiological and temporal boundaries and cut-offs,
severity strata, and standards used.
3.5.1. Level of detail
Deﬁnitions for key AEFIs varied widely in terms of terminology
and level of detail. For example, Pasternak et al., 2012 deﬁnes mis-
carriage/spontaneous abortion as “abortion occurring between”
certain weeks of gestation [22]; in contrast, Nishioka et al. [23] cite
the WHO  1970 deﬁnition, which deﬁnes the same event as “any
non-deliberate interruption of an intrauterine pregnancy before
the 28th week of gestation in which the fetus is dead when
expelled”. Other deﬁnitions use similar, but not identical, termi-
nology, such as “pregnancy loss,” “fetal death,” and “intrauterine
death.”
3.5.2. Boundaries and cut-offs
Criteria for many deﬁned AEFIs stipulate that a temporal or
physiological threshold must be met  or exceeded, such as fever
being deﬁned as temperature at or above 38 degrees Celsius.
Here, study deﬁnitions revealed both stark and nuanced differences
that may  result in unexpected disagreements on AEFI classiﬁ-
cation across studies. This is best demonstrated by examining
included studies’ gestational age cut-offs for miscarriage versus
T.R. Fulton et al. / Vaccine 33 (2015) 6453–6465 6457
Table  2
Characteristics of selected studies.
Study author and
year
[reference]
Continent Study design Type of vaccine Primary study outcome Safety-related
outcome (if different
from primary
outcome)
Abzug, 2013 [28] North America Prospective
cohort
Inﬂuenza Safety and immunogenicity of H1N1 vaccine in HIV infected
pregnant women
Adedinsewo,
2013 [29]
North America Retrospective
cohort
Inﬂuenza Maternal vaccination impact on prematurity and SGA
Auffret, 2013 [30] Europe Prospective
cohort
Inﬂuenza Adverse event and vaccine safety of inﬂuenza vaccine in
pregnant women
Baker, 1988 [31] North America Prospective
cohort
GBS Antibody level in immunized pregnancies and in newborns Maternal adverse
effects
Baker,  2003 [32] North America RCT GBS Safety and immunogenicity in pregnant women Maternal adverse
effects
Bednarczyk,
2012† [12]
Multiple Review Inﬂuenza Safety of inﬂuenza immunization for fetus and neonate
Black,  2004 [33] North America Retrospective
cohort
Inﬂuenza Impact of inﬂuenza vaccination on pregnant women and risk
of  illness and safety in newborns
Cantu, 2013 [34] North America Retrospective
cohort
Inﬂuenza Association of inﬂuenza vaccination with increased risk of
adverse pregnancy outcomes
Cavalcanti, 2007
[35]
South America Before/after Yellow fever Effect of yellow fever vaccine on newborn malformation rates
Chambers, 2013
[36]
North America Prospective
cohort
Inﬂuenza Risk and safety of H1N1 vaccines in women exposed during
pregnancy
Chavant, 2013
[37]
Europe Prospective
cohort
Inﬂuenza Safety of a/H1N1 vaccination during pregnancy
Christian, 2011
[38]
North America Prospective
cohort
Inﬂuenza Inﬂammatory response to vaccination in pregnant women
Conlin, 2013 [39] North America Retrospective
cohort
Inﬂuenza Safety of H1N1 vaccine in Pregnant US military women
Cottin,  2013† [40] Multiple Review Yellow fever Adverse events from yellow fever vaccine
da  Silva, 2011
[41]
South America Prospective
cohort
Rubella Safety of Rubella vaccine during pregnancy
Dana, 2009 [42] Multiple Prospective
cohort
HPV Safety of HPV vaccine during pregnancy- pregnancy outcomes
and birth defects
De  Vries, 2014
[43]
Europe Prospective
cohort
Inﬂuenza Adverse events of adjuvanted a/H1N1 vaccination during
pregnancy
Ergenoglu, 2012
[44]
Europe Prospective
cohort
Rubella Safety of Rubella vaccine during pregnancy
Harjulehto-
Mervaala, 1994
[45]
Europe Prospective
cohort
OPV Fetal development and perinatal outcome after OPV
vaccination during pregnancy
Hashim, 2012*
[18]
Africa Cross-sectional Cholera Birth outcomes between exposed and unexposed pregnancies
Heikkinen, 2012
[24]
Multiple Prospective
cohort
Inﬂuenza Inﬂuenza vaccine safety in pregnant women and neonates
Huang, 2013 [46] Asia Prospective
cohort
Rabies Safety of post-exposure prophylaxis during pregnancy
Kallen, 2012 [47] Europe Retrospective
cohort (registry
data)
Inﬂuenza Pregnancy outcomes post H1N1 vaccination
Kharbanda, 2012
[48]
North America Prospective
cohort
Inﬂuenza Adverse effects from trivalent or monovalent inﬂuenza
vaccination during pregnancy
Kharbanda, 2013
[49]
North America Retrospective
cohort
Inﬂuenza Adverse events between exposed and unexposed pregnant
women, speciﬁcally, preterm and small for gestational age
births
Launay, 2012
[50]
Europe Prospective
cohort
Inﬂuenza Consequences of maternal vaccination on pregnancy outcomes
and maternal seroprotection at delivery
Lehmann, 2003*†
[19]
Asia Review Pneumococcal Pneumococcal vaccine safety review
Lin,  2012 [51] Asia Retrospective
cohort
Inﬂuenza Adverse events after AdimFlu-S vaccination in pregnant
women
Lin, 2013 [52] Asia Prospective
cohort
Inﬂuenza Immune response of the three vaccine viral strains Incidence of
pre-speciﬁed adverse
events and all
serious/non-serious
adverse events
Louik,  2013 [53] North America Prospective
cohort
Inﬂuenza Safety of H1N1 vaccine during pregnancy
Ludvigsson, 2013
[54]
Europe Retrospective
cohort
Inﬂuenza Adverse pregnancy outcomes from inﬂuenza H1N1 vaccination
Mackenzie, 2012
[55]
Europe Prospective
cohort
Inﬂuenza Adverse events and pregnancy outcome post H1N1 vaccination
Makris, 2012†
[56]
Multiple Review Multiple Safety of various maternal vaccines
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Table 2 (Continued)
Study author and
year
[reference]
Continent Study design Type of vaccine Primary study outcome Safety-related
outcome (if different
from primary
outcome)
Moro, 2011 [57] North America Retrospective
cohort
Inﬂuenza
(monovalent)
Adverse events of monovalent inﬂuenza vaccination during
pregnancy
Moro, 2011 [58] North America Retrospective
cohort
Inﬂuenza
(trivalent)
Adverse events of inﬂuenza vaccine between exposed and
unexposed pregnancies
Moro, 2012† [59] Multiple Review Inﬂuenza Safety of inﬂuenza vaccines on pregnant women  and neonates
with emphasis on a/H1N1 monovalent vaccine
Moro,  2013 [60] North America Retrospective
cohort
Inﬂuenza Maternal and infant outcomes for vaccinated pregnant women
Moro,  2014 [61] North America Retrospective
cohort
Hepatitis Vaccine maternal adverse effects
Munoz, 2001 [7] North America RCT Multiple Safety and immunogenicity of PSV in pregnant women
Munoz, 2003 [62] North America RCT RSV Safety and immunogenicity of RSV vaccine during pregnancy
Munoz, 2005 [63] North America Retrospective
cohort
Inﬂuenza Safety of inﬂuenza vaccination during pregnancy
Munoz, 2014 [64] North America RCT Tdap Safety of Tdap vaccine during pregnancy Infant response to
DTaP vaccine
Naleway, 2014†
[65]
North America Review Inﬂuenza Safety of inﬂuenza vaccination during pregnancy
Nishioka, 1998
[23]
South America Case control Yellow fever Effect of yellow fever vaccination on spontaneous abortion
Nordin, 2013 [66] North America Retrospective
cohort
Inﬂuenza Adverse Events after ﬁrst trimester inﬂuenza vaccination
Nordin, 2014 [67] North America Retrospective
cohort
Inﬂuenza Impact of inﬂuenza vaccine on preterm and SGA
Omon, 2011 [68] Europe Prospective
cohort
Inﬂuenza Safety of non-adjuvanted H1N1 vaccine on pregnant women
Oppermann,
2012  [69]
Europe Prospective
cohort
Inﬂuenza H1N1 vaccine safety in pregnancy
Orenstein, 2012*†
[20]
Africa Review Multiple Develop estimates of maternal and neonatal background
morbidity and mortality
Pardon, 2011 [70] South America Prospective
cohort
Rubella Fetal adverse events after rubella vaccination in pregnant
women
Pass, 2009 [71] North America RCT CMV  CMV  infection Vaccine adverse
effects and birth
outcomes
Pasternak, 2012
[22]
Europe Retrospective
cohort (registry
data)
Inﬂuenza a/H1N1 vaccination association with major birth defects,
preterm birth and fetal growth restriction
Pasternak, 2012
[72]
Europe Retrospective
cohort (registry
data)
Inﬂuenza Risk of fetal death and spontaneous abortion from vaccination
against a/H1N1
Pitisuttithum,
2011 [73]
Asia RCT HIV Adverse events related and unrelated to pregnancy
Quiambao, 2007*
[21]
Asia RCT Pneumococcal Immunogenicity and antibody transfer after pneumococcal
vaccination
Santosham, 2001
[74]
North America RCT Multiple Safety and immunogenicity of Hib vaccines verses
pneumococcal
Sato, 2011 [75] South America Prospective
cohort
Rubella Fetal adverse events after rubella vaccination in pregnant
women
Congenital rubella
infection in newborns
after exposure to
vaccine
Shakib, 2013 [76] North America Retrospective
cohort
Tdap Safety of Tdap vaccine during pregnancy
Shefﬁeld, 2011
[77]
North America Prospective
cohort
Hepatitis Feasibility and immunogenicity of an accelerated hepatitis B
vaccine schedule in high-risk pregnant women
Maternal adverse
effects
Shefﬁeld, 2012
[78]
North America Retrospective
cohort
Inﬂuenza First trimester inﬂuenza vaccination on neonatal outcomes
Shefﬁeld, 2013†
[79]
Multiple Review Multiple Standardized vital signs and laboratory assessments during
maternal vaccine trials
Silveira, 1995
[80]
South America Case control TT Safety outcomes of TT in newborns
Suzano, 2006
[81]
South America Retrospective
cohort
Yellow fever Safety of yellow fever during pregnancy
Talbot, 2010 [82] North America Cross-sectional Tdap Safety of Tdap less than 2 year after previous tetanus
vaccination
Tavares, 2011
[83]
Europe Prospective
cohort
Inﬂuenza Safety outcomes in exposed and unexposed women
Tavares, 2013†
[84]
Multiple Review Herpes simplex Risk of spontaneous abortion following HSV vaccination
Thomas, 2012†
[85]
Multiple Review Yellow fever Adverse events from yellow fever vaccine in vulnerable
populations
Toback, 2012 [86] North America Retrospective
cohort
Inﬂuenza Safety of LAIV during pregnancy
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Table  2 (Continued)
Study author and
year
[reference]
Continent Study design Type of vaccine Primary study outcome Safety-related
outcome (if different
from primary
outcome)
Tsai, 2010 [87] Europe Retrospective
cohort
Inﬂuenza Pregnancy outcomes in exposed and unexposed women
Wilson, 2008 [88] North America Retrospective
cohort (registry
data)
Varicella Outcomes after inadvertent exposure to Varicella vaccine
during pregnancy
Wise, 2000 [89] North America Retrospective
cohort
Varicella Adverse events from varicella vaccine
Wright, 1999
[90]
North America RCT HIV Safety of rgp120 during pregnancy
Zheteyeva, 2012
[91]
North America Retrospective
cohort
Tdap Safety of Tdap in pregnant women
Zheteyeva, 2013
[92]
North America Retrospective
cohort
Meningococcal Safety of meningococcal vaccine in pregnancy
* Study conducted in lower- or lower-middle-income country.
† Systematic review.
Table 3
Top ten adverse events most frequently reported in selected studies.
Adverse event Number of times
reported
Miscarriage/spontaneous abortion 31
Preterm birth 31
Stillbirth 25
Fever, maternal 19
Pre-eclampsia 14
Site pain 12
Low birth weight 12
Elective abortion 11
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We  therefore recommend that case deﬁnitions for all monitoredRespiratory distress 11
Small for gestational age 11
tillbirth. These cut-offs are deﬁned using language that appears
airly homogenous (Table 4); however, upon close examination,
ubstantial variations in gestational age thresholds become evi-
ent (Fig. 2a and b). One key issue is the fact that classiﬁcation
f miscarriage versus stillbirth will depend on whether the stated
ut-off is inclusive or exclusive of (i.e., greater than versus greater
han/equal to) the given gestational week. Such nuances in detail,
oth regarding these cut-offs as well as other factors (for example,
ome deﬁnitions also establish different criteria for when gesta-
ion actually begins) may  introduce further uncertainty into the
lassiﬁcation of fetal death.
In addition, some stillbirth and miscarriage deﬁnitions also
ncluded fetal mass criteria. This may  raise the question of how
o classify a fetal death should it (for example) meet gestational
ge, but not mass threshold, for a given deﬁnition.
.5.3. Severity strata
Eighteen papers in our review speciﬁed adverse event strata.
or example, the Heikkinen et al., 2012 deﬁnition of stillbirth
ifferentiated between “early fetal loss” as fetal death before 22
eeks gestation and “late fetal loss” as death between 22 and 28
eeks [24]. Other papers provided strata for preterm birth, low
irth weight, and other AEFIs; these deﬁnitions varied on criteria,
hresholds, and number of strata for a given AEFI (Supplemental
able 2).
.5.4. Standards used
Small for gestational age deﬁnitions exhibited variation in these of fetal measurement standards. For example, Chambers et al.
36] and Cantu et al. [34] utilize Brenner and Lubchenco curves,
espectively.3.6. Deﬁning an “Adverse Event”
In addition to the variability in deﬁnition provision and AEFI
reporting, studies demonstrated substantial variation in what com-
prises an “adverse event”. Twenty-one studies offered explicit
deﬁnitions of the term “adverse event” (Table 5). Among these
deﬁnitions, six distinct variants of the term “adverse event” were
described, e.g., “adverse obstetric event,” “adverse event of spe-
cial interest,” etc. These deﬁnitions range broadly in speciﬁcity
and, among deﬁnitions describing the same term, demonstrate
little agreement even relative to that exhibited by more spe-
ciﬁc AEFI deﬁnitions. Table 5 summarizes all deﬁnitions provided
for the term “adverse event” and variants used in selected
studies.
4. Discussion
Our study revealed that three major forms of adverse vari-
ability currently exist among published maternal immunization
studies, including variability in: AEFI deﬁnitions, AEFI reporting,
and deﬁning what constitutes an adverse event. Each of these can
be mitigated by the future adoption of standardized deﬁnitions,
which should be of sufﬁcient detail and consistency of language
to avoid ambiguity. Speciﬁcally, deﬁnitions should be consistent in
deﬁning key terms, diagnostic methodology, cut-offs, thresholds,
severity strata, and physiological or other evaluative criteria. The
high frequency with which we found certain AEFIs to be deﬁned
and reported (stillbirth, miscarriage, preterm birth, etc.) may  also
inform the priorities of standardization efforts.
Importantly, investigators may  proactively work to eliminate
between-study variability through clear and consistent reporting of
AEFI deﬁnitions and outcomes in future publications. We  observed
that nearly all papers in our review that examined AEFIs as a pri-
mary study outcome provided deﬁnitions for each AEFI in Section
2. In addition, these investigators took care in Section 3 to report on
each AEFI previously deﬁned, whether or not they were detected.
Although signiﬁcant heterogeneity was still evident across the
AEFI deﬁnitions provided in these papers, the consistency of this
deﬁnition-and-reporting approach helped considerably to mini-
mize confusion in reporting of outcomes, compared to studies that
provided no deﬁnitions (or that only provided deﬁnitions paren-
thetically in Section 3).AEFIs in maternal immunization studies be explicitly provided in
Section 2 of the study report or an online supplement, with the
incidence of each deﬁned adverse event reported on in Section 3 or
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Table 4
List of unique adverse event deﬁnitions provided by selected studies. Only adverse events explicitly deﬁned by study authors (i.e., those studies deﬁning AEFIs beyond simply
referring to the coding/classiﬁcation scheme used) are shown. Deﬁnitions with an asterisk are those used in studies conducted in lower-middle-income countries (LMICs).
AEFI target
(mother,
neonate, fetus)
AEFI type AEFI type, detail AEFI deﬁnition, description, or classiﬁcation reference used [references]
Mother Local Local reaction Pain, redness, or swelling [82]
Redness, swelling, induration or pain conﬁrmed by comparison to a 2 cm circle (≥circle
records as positive) [21]
Systemic Anaphylaxis Physician assessment or Brighton deﬁnition [57,58]
Sudden onset (<3d after vaccination) and rapid progression of symptoms involving
multiple systems organ classes: dermatologic, cardiovascular, and respiratory (per
Brighton collaboration deﬁnition) [40]
Bell’s palsy Brighton deﬁnition [57,58]
Fever “Feeling feverish” and/or temperature measured to be >100.4 ◦F [82]
Temperature ≥ 38 ◦C [51,52]
Guillain-Barre
syndrome
Physician assessment or Brighton deﬁnition [57,58]
Inﬂuenza-like
illness
Oral temperature > 37.8 ◦C with at least one inﬂuenza-like symptom (cough, sore throat,
rhinorrhea, nasal obstruction) [50]
Mild adverse event Headache, fever, or myalgia [81]
Pregnancy-
related
Abnormal
pregnancy
Ectopic pregnancy/spontaneous abortion/stillborn delivery [87]
Maternal death Death from direct or indirect obstetric causes during pregnancy or <42 days after
pregnancy termination [20]*
Normal pregnancy Normal, live-born delivery [87]
Pre-eclampsia Pregnancies with an ICD-9-CM-coded diagnosis of preeclampsia (642.4×–642.7×)
occurring during pregnancy [39]
Pregnancy
complications
Any or none, based on self-report [75]
Preterm labor Pregnancies with an ICD-9-CM-coded diagnosis of threatened premature labor (hereafter
referred to as premature labor; 644.0×) or early (spontaneous) onset of delivery occurring
during pregnancy with initial diagnosis of either premature labor or premature delivery at
least 1 day after pandemic H1N1 or seasonal inﬂuenza immunization [39]
Severe acute
maternal morbidity
Direct or indirect obstetric complications that threaten the woman’s survival but do not
lead to her death [20]*
Fetus In  utero Elective abortion Induced termination of a pregnancy due to personal choice or medical reasons prior to 20
weeks post-conception day (or 22 weeks of gestation) [83]
Fetal death Spontaneous abortion and stillbirth combined [42]
Nonviable conceptus in pregnancies after more than 20 weeks amenorrhea [72]
Induced abortion Therapeutic or elective abortion [87]
Intrauterine fetal
death
Fetal death with unknown gestation time [57,58]
Late fetal death Fetal death occurring ≥20 w gestation [88]
Miscarriage/
spontaneous
abortion
Abortion occurring between start of week 7 and end of week 22 of gestation [22]
Any non-deliberate interruption of an intrauterine pregnancy before the 28th week of
gestation (since the last menstrual period) in which the fetus is dead when expelled (WHO
1970) [23]
Delivery between 14 w and 21 w + 6 days gestation [50]
Delivery prior to 20 weeks [34]
Fetal death occurring <20 weeks gestation [57–59,61,91,92]
Intrauterine death of a fetus under 500 g or of gestational age under 22 weeks’
amenorrhea [37]
Intrauterine death of fetus at <24 w gestation [83]
Loss before 22 weeks gestation [24]
Pregnancy loss before week 22 [43]
Pregnancy termination within 20 weeks of conception [18]*
Spontaneous loss of conceptus before 20 weeks amenorrhea [42]
Spontaneous pregnancy loss at <20 gestational weeks [36]
Termination of a pregnancy without human interference prior to 20 weeks
post-conception day (or 22 weeks of gestation) [84]
Loss of a fetus <500 g or prior to 22 weeks gestation [75]
Stillbirth Death at birth [20]*
Delivery of a non-viable fetus at or after 20 weeks [34]
Delivery of a non-viable fetus at or after 22 completed weeks [72]
Fetal death occurring >20 weeks gestation [57,58]
Fetal death of ≥500 g [57–60]
Fetal demise ≥20 w gestation [91,92]
Fetus born after 20 weeks gestation without pulse [18]*
Intrauterine death of a fetus over 500 g or of gestational age more than 22 weeks’
amenorrhea [37]
Intrauterine death of fetus at ≥24 w gestation [83]
Loss of a fetus ≥500 g or at 22 weeks gestation or later [75]
Pregnancy loss after week 22 [43]
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Table  4 (Continued)
AEFI target
(mother,
neonate, fetus)
AEFI type AEFI type, detail AEFI deﬁnition, description, or classiﬁcation reference used [references]
Neonate Congenital
abnormality
Gross
malformation
Physical defect present in baby at birth, including any abnormality visible on a naked baby
(e.g. cleft lip or palate, Down syndrome, spina biﬁda, limb defects, etc.) [43]
“Various” Classiﬁed using CDC and Prevention Metropolitan Atlanta Congenital Defects Program
guidelines. All structural–morphological, chromosomal or genetic anomalies were
included in this deﬁnition, regardless of whether the fetus was  delivered dead or alive, and
included birth defects identiﬁed by prenatal ultrasound, amniocentesis or examination of
the products of conception after elective or spontaneous abortion [83]
Perinatal Early neonatal
death
Death of a liveborn infant within the ﬁrst week of life [20]*
Low Apgar score Score < 7 at 5 min  [50,54]
Low birth
weight
Birth weight < 2500 g [22,54,75,84]
Birth weight < 2500 g measured by study team within 7 days of life or extracted from
ofﬁcial birth records [20]*
Postterm birth Birth 42 weeks or greater [43]
Preterm birth Birth ≤ 36 completed weeks [54]
Birth at <37 weeks gestation [75,84]
Birth between 22 w and 36 w + 6 days gestation [50]
Birth between 32 and 36 weeks [43]
Clinical estimate of gestational age at birth of less than 37 completed weeks [29]
Estimated gestational age <37 completed weeks as determined by ultrasound, last
menstrual period, or validated exam within 7 days of life [20]*
Live birth <37 weeks gestation [91,92]
Small for
gestational age
<10th percentile for sex and gestational age in live born infants using standard US growth
charts for full and preterm infants (NCHS 2000 growth curves or Lubchenko) [36]
<10th percentile of gestational age-speciﬁc birth weight within cohort [54,66]
Brenner’s standard for fetal growth less than the 10th percentile [34]
Children with measurements of weight, length, and head circumference <2 SD than
reference values (calculated from full-term infant measurements of combined reference
cohorts) [45]
Lowest 10th percentile of birth weight for each gestational week [29]
Measurements <2 SD from expected weight [47]
Very low birth
weight
Birth weight under 1500 g [42]
Very preterm birth Birth between 22 and 31 weeks [43]
Birth less than 32 weeks gestation [42]
Postnatal Atypical infant
behavior
Deviation from normal feeding, crying, defecating, urinating, sleeping, and growing
behavior as deﬁned by mother [18]*
Infant death Live births dying later in infancy [18]*
Late neonatal death Death of a liveborn infant between 1 and 4 weeks of life [20]*
Recurring illness Illness lasting more than two weeks or occurring twice or more often [18]*
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Rn online supplement. If a classiﬁcation system is used, it should be
ited in Section 2. To further reduce ambiguity in comparing data,
e recommend that classiﬁcation codes be provided in the results
ables for each detected adverse event. These recommendations are
ummarized in Table 6.
Special attention must be paid to AEFI deﬁnitions used in studies
onducted in low- and low-middle-income countries. It may  be rea-
oned that AEFI deﬁnitions need to take into account factors such as
he relative lack of diagnostic capacity, high patient load, etc. that
ay  be present in some low-resource settings, which may  imply a
reference for less-speciﬁc AEFI deﬁnitions compared to other con-
exts. An example would be a requirement to conﬁrm preterm birth
ia early-pregnancy ultrasound in a setting with limited access to
ophisticated diagnostic equipment.
Due to the very small number of studies conducted in low-
nd low-middle-income (LMIC) countries in our review, we  are
imited in our ability to assess meaningful differences in AEFI def-
nitions in these contexts. Some of the unique AEFI deﬁnitions
rovided in our LMIC studies appear to reﬂect less interest in the
peciﬁcs of an adverse event, and more interest in the sensitive
etection of any abnormal event (e.g., “atypical infant behavior”
nd “severe acute maternal morbidity,” two catch-all deﬁnitions
nique to LMIC studies). We  do not, however, recommend that rigor
n AEFI deﬁnitions should be relaxed for studies in LMIC contexts.
ather, considerations speciﬁc to low-resource countries should begiven careful thought in the process of developing standard AEFI
deﬁnitions.
Our study has additional limitations. We  searched for articles
via four major literature databases, but we did not hand-search
individual journals or gray literature. Maternal immunization stud-
ies that reported no safety outcomes may  nevertheless have
monitored for AEFIs using established case deﬁnitions; however,
these studies were not included in our review. Finally, six older
(pre-2000) articles were excluded due to inability to access the
full papers, and ﬁve non-English candidate articles were not
included in the ﬁnal review due to lack of translation capacity
(Fig. 1).
Efforts to standardize maternal immunization AEFI deﬁnitions
are ongoing, with active efforts underway by WHO, the Brighton
Collaboration, and other contributors [25–27]. Our review has pro-
vided a more complete picture of the landscape of maternal AEFI
deﬁnitions currently in use, to help inform how best to approach
standardization. One of the principal standardization efforts, the
Global Alignment of Immunization Safety Assessment in Pregnancy
(GAIA), is a WHO/Brighton Collaboration joint project aiming to
provide standards and tools to establish a globally shared under-
standing of outcomes and approaches to monitoring them, with
speciﬁc focus on LMIC needs and requirements.
Future standardized AEFI deﬁnitions developed through such
initiatives will help ensure consistency of data and facilitate data
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Table 5
List of deﬁnitions of the term “adverse event” and variations, as detailed in selected studies.
Term Deﬁnition [reference]
Adverse event Any undesired, noxious or pathological change in participants as indicated by physical signs, symptoms, and/or
laboratory changes that occurred following administration of one of the vaccines, whether or not considered
vaccine-related (includes intercurrent illnesses or injuries and unexpected exacerbations of pre-existing
conditions) [73]
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical
product regardless of its causal relationship to the study treatment. An AE can therefore be “any unfavorable and
unintended sign(s), symptoms(s) or condition temporally related with the use of the investigational product” [77]
Adverse obstetric event New, prespeciﬁed, medically attended pregnancy-related comorbidities or pregnancy complications [48]
Medically signiﬁcant adverse event Requiring two or more visits to a physician for the same condition or that resulted in hospitalization or an ER visit
[73]
Adverse event of special interest Any event considered as worthy of closer follow-up as described in recommendations for the Pharmacovigilance
Plan following the administration of H1N1 pandemic vaccines [83]
Medically-attended adverse event Event leading to an otherwise unscheduled visit to or from medical personnel for any reason, including visits to an
accident and emergency department [83]
Neonatal adverse event Visits with prespeciﬁed ICD-9 codes that occur from birth through 30 days old [49]
Serious adverse event Deﬁned per FDA guidelines [71]
Any untoward medical occurrence that: resulted in death, was life-threatening, required hospitalization or
prolongation of existing hospitalization, resulted in disability/incapacity, or was a congenital anomaly/birth defect
in  the child of a study participant [78]
Reports containing information that the AE resulted in death, hospitalization, prolongation of hospitalization,
life-threatening illness, persistent or signiﬁcant disability, or congenital anomalies. Deﬁnition modiﬁed to exclude
reports on hospitalizations for delivery unless they required prolonged stay in a hospital due to delivery
complications or postpartum conditions [90]
AEs resulting in or prolonging hospital admission, is life-threatening, fatal or resulting in signiﬁcant or persisting
disability [55]
AEs including death, hospitalization, and cause for hospitalization and permanently disabling conditions [64]
Any adverse experience any time after vaccination that resulted in any of the following outcomes: death, a
life-threatening adverse experience, inpatient hospitalization or prolongation of existing hospitalization or a
persistent or signiﬁcant disability/incapacity, a congenital anomaly, or an important medical event that, based
upon medical judgment, may  have required medical or surgical intervention to prevent one of those outcomes [82]
Deaths, life-threatening events, hospitalizations, persistent or signiﬁcant disabilities, congenital anomalies, and
other events of medical importance (FDA regulations) [89]
Any event leading to hospitalization, prolonging hospitalization, entailing permanent handicap or disability, and
life-threatening or fatal condition (per French public health code) [37]
VAERS Report classiﬁed as serious if resulting in death, life-threatening illness, hospitalization or prolongation of
hospitalization, permanent disability, or congenital anomaly [57–60]
Table 6
Summary of recommendations for future efforts in standardization of AEFI
deﬁnitions.
Recommendation 1. Case
deﬁnitions should be of
sufﬁcient detail and
consistency of language to
avoid ambiguity with respect
to:
-  Cut-offs/thresholds deﬁning related AEs
- Severity strata
-  Physiological or other evaluative criteria
- Diagnostic methodology
- Deﬁnition of key terms (e.g., gestational
age as weeks of amenorrhea or as weeks
post-conception)
Recommendation 2. Effort
should be made to encourage
the following qualities:
- Consistent reporting in Section 2 of AE
deﬁnitions used or speciﬁc classiﬁcation
schemes/codes (e.g., ICD-9 codes) in all
studies
-  Consistent reporting in results of all AEs
deﬁned
Recommendation 3. Explore the use of frequency analysis to inform
standardization efforts where multiple case deﬁnitions for a given AE are
available
Recommendation 4. Prioritize appropriate standardization for future studies
over “back-compatibility” with deﬁnitions in previous studies, given the
substantial variability in existing deﬁnitions
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The ﬁndings and conclusions in this report are those of the
authors. The authors alone are responsible for the views expressedomparisons and pooling; however, they should be accompanied
y consistency of reporting. We  believe that this is achievable, and
hat improving adverse event reporting practices is a ﬁrst step that
hould be taken without hesitation. In view of a swiftly expandingglobal maternal immunization agenda, we have no reason to
delay.
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